Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
CSII's Cash-to-Debt is ranked higher than
94% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: 2.55 vs. CSII: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
CSII' s Cash-to-Debt Range Over the Past 10 Years
Min: 1.11  Med: N/A Max: No Debt
Current: No Debt
Equity-to-Asset 0.71
CSII's Equity-to-Asset is ranked higher than
65% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. CSII: 0.71 )
Ranked among companies with meaningful Equity-to-Asset only.
CSII' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.4  Med: 0.51 Max: 0.94
Current: 0.71
-1.4
0.94
Interest Coverage No Debt
CSII's Interest Coverage is ranked higher than
94% of the 222 Companies
in the Global Medical Devices industry.

( Industry Median: 86.37 vs. CSII: No Debt )
Ranked among companies with meaningful Interest Coverage only.
CSII' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 10.27
Beneish M-Score: -3.66
WACC vs ROIC
16.13%
-68.76%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % -14.78
CSII's Operating Margin % is ranked lower than
64% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 2.62 vs. CSII: -14.78 )
Ranked among companies with meaningful Operating Margin % only.
CSII' s Operating Margin % Range Over the Past 10 Years
Min: -60.63  Med: -21.58 Max: 3.82
Current: -14.78
-60.63
3.82
Net Margin % -14.74
CSII's Net Margin % is ranked lower than
65% of the 304 Companies
in the Global Medical Devices industry.

( Industry Median: 1.55 vs. CSII: -14.74 )
Ranked among companies with meaningful Net Margin % only.
CSII' s Net Margin % Range Over the Past 10 Years
Min: -56.49  Med: -23.14 Max: 13.13
Current: -14.74
-56.49
13.13
ROE % -26.36
CSII's ROE % is ranked lower than
68% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 1.31 vs. CSII: -26.36 )
Ranked among companies with meaningful ROE % only.
CSII' s ROE % Range Over the Past 10 Years
Min: -99.5  Med: -47.59 Max: 10
Current: -26.36
-99.5
10
ROA % -19.31
CSII's ROA % is ranked lower than
66% of the 327 Companies
in the Global Medical Devices industry.

( Industry Median: 0.06 vs. CSII: -19.31 )
Ranked among companies with meaningful ROA % only.
CSII' s ROA % Range Over the Past 10 Years
Min: -58.12  Med: -30.3 Max: 6.68
Current: -19.31
-58.12
6.68
ROC (Joel Greenblatt) % -64.93
CSII's ROC (Joel Greenblatt) % is ranked lower than
65% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 4.26 vs. CSII: -64.93 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
CSII' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -4509.29  Med: -177.88 Max: 88.2
Current: -64.93
-4509.29
88.2
3-Year Revenue Growth Rate 4.60
CSII's 3-Year Revenue Growth Rate is ranked higher than
51% of the 237 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. CSII: 4.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
CSII' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -7 Max: 23.9
Current: 4.6
0
23.9
3-Year EBITDA Growth Rate 16.90
CSII's 3-Year EBITDA Growth Rate is ranked higher than
64% of the 208 Companies
in the Global Medical Devices industry.

( Industry Median: 5.10 vs. CSII: 16.90 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
CSII' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -27.5 Max: 79.4
Current: 16.9
0
79.4
3-Year EPS without NRI Growth Rate 15.70
CSII's 3-Year EPS without NRI Growth Rate is ranked higher than
67% of the 203 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. CSII: 15.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
CSII' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -66.2  Med: -9.05 Max: 81.2
Current: 15.7
-66.2
81.2
GuruFocus has detected 3 Warning Signs with Cardiovascular Systems Inc $CSII.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» CSII's 10-Y Financials

Financials (Next Earnings Date: 2017-05-03)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

CSII Guru Trades in Q1 2016

Steven Cohen 102,200 sh (New)
Paul Tudor Jones 10,900 sh (New)
Mario Gabelli 36,300 sh (+3.13%)
Mairs and Power 246,202 sh (unchged)
Jim Simons Sold Out
» More
Q2 2016

CSII Guru Trades in Q2 2016

Steven Cohen 403,824 sh (+295.13%)
Mario Gabelli 36,400 sh (+0.28%)
Paul Tudor Jones Sold Out
Mairs and Power 121,202 sh (-50.77%)
» More
Q3 2016

CSII Guru Trades in Q3 2016

Jim Simons 174,100 sh (New)
Paul Tudor Jones 13,000 sh (New)
Mario Gabelli 36,400 sh (unchged)
Mairs and Power 76,002 sh (-37.29%)
Steven Cohen 171,100 sh (-57.63%)
» More
Q4 2016

CSII Guru Trades in Q4 2016

John Hussman 117,000 sh (New)
Paul Tudor Jones 18,806 sh (+44.66%)
Mario Gabelli 36,400 sh (unchged)
Steven Cohen Sold Out
Mairs and Power 75,762 sh (-0.32%)
Jim Simons 131,100 sh (-24.70%)
» More
» Details

Insider Trades

Latest Guru Trades with CSII

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NAS:VASC, NAS:KTWO, NAS:MDXG, NAS:OFIX, OTCPK:SBMAF, NAS:CNMD, NYSE:ITGR, OTCPK:MZRTF, NAS:SPNC, NAS:GNMK, NAS:BABY, NYSE:CRY, OTCPK:NMRD, NAS:XENT, NAS:VRAY, NAS:ARAY, NYSE:IVC, NAS:ELOS, NAS:EXAC, NAS:AXGN » details
Traded in other countries:R7Y1.Germany,
Headquarter Location:USA
Cardiovascular Systems Inc is a medical technology company. It is engaged in developing, manufacturing, and marketing devices for the treatment of vascular diseases.

Cardiovascular Systems is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generates the vast majority of its revenue in the United States.

Ratios

vs
industry
vs
history
Forward PE Ratio 196.08
CSII's Forward PE Ratio is ranked lower than
99% of the 111 Companies
in the Global Medical Devices industry.

( Industry Median: 21.79 vs. CSII: 196.08 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PB Ratio 8.80
CSII's PB Ratio is ranked lower than
85% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 3.11 vs. CSII: 8.80 )
Ranked among companies with meaningful PB Ratio only.
CSII' s PB Ratio Range Over the Past 10 Years
Min: 0.18  Med: 5.66 Max: 14.5
Current: 8.8
0.18
14.5
PS Ratio 5.08
CSII's PS Ratio is ranked lower than
66% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 3.20 vs. CSII: 5.08 )
Ranked among companies with meaningful PS Ratio only.
CSII' s PS Ratio Range Over the Past 10 Years
Min: 0.24  Med: 2.37 Max: 7.39
Current: 5.08
0.24
7.39
Price-to-Free-Cash-Flow 177.77
CSII's Price-to-Free-Cash-Flow is ranked lower than
94% of the 112 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. CSII: 177.77 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
CSII' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 139.23  Med: 160.48 Max: 179.58
Current: 177.77
139.23
179.58
Price-to-Operating-Cash-Flow 126.00
CSII's Price-to-Operating-Cash-Flow is ranked lower than
96% of the 140 Companies
in the Global Medical Devices industry.

( Industry Median: 20.26 vs. CSII: 126.00 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
CSII' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 98.69  Med: 113.76 Max: 127.28
Current: 126
98.69
127.28
EV-to-EBIT -30.79
CSII's EV-to-EBIT is ranked lower than
99.99% of the 275 Companies
in the Global Medical Devices industry.

( Industry Median: 24.54 vs. CSII: -30.79 )
Ranked among companies with meaningful EV-to-EBIT only.
CSII' s EV-to-EBIT Range Over the Past 10 Years
Min: -35.1  Med: -13.3 Max: 9.1
Current: -30.79
-35.1
9.1
EV-to-EBITDA -36.96
CSII's EV-to-EBITDA is ranked lower than
99.99% of the 300 Companies
in the Global Medical Devices industry.

( Industry Median: 19.31 vs. CSII: -36.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
CSII' s EV-to-EBITDA Range Over the Past 10 Years
Min: -37.34  Med: -11.5 Max: 6.7
Current: -36.96
-37.34
6.7
Current Ratio 3.80
CSII's Current Ratio is ranked higher than
72% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 2.38 vs. CSII: 3.80 )
Ranked among companies with meaningful Current Ratio only.
CSII' s Current Ratio Range Over the Past 10 Years
Min: 1.27  Med: 3.91 Max: 17.17
Current: 3.8
1.27
17.17
Quick Ratio 3.30
CSII's Quick Ratio is ranked higher than
73% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. CSII: 3.30 )
Ranked among companies with meaningful Quick Ratio only.
CSII' s Quick Ratio Range Over the Past 10 Years
Min: 1.18  Med: 3.36 Max: 17.17
Current: 3.3
1.18
17.17
Days Inventory 170.61
CSII's Days Inventory is ranked lower than
66% of the 289 Companies
in the Global Medical Devices industry.

( Industry Median: 130.04 vs. CSII: 170.61 )
Ranked among companies with meaningful Days Inventory only.
CSII' s Days Inventory Range Over the Past 10 Years
Min: 37.97  Med: 113.08 Max: 170.61
Current: 170.61
37.97
170.61
Days Sales Outstanding 48.09
CSII's Days Sales Outstanding is ranked higher than
80% of the 272 Companies
in the Global Medical Devices industry.

( Industry Median: 68.94 vs. CSII: 48.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
CSII' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.38  Med: 55.96 Max: 61.98
Current: 48.09
47.38
61.98
Days Payable 74.71
CSII's Days Payable is ranked higher than
58% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 59.71 vs. CSII: 74.71 )
Ranked among companies with meaningful Days Payable only.
CSII' s Days Payable Range Over the Past 10 Years
Min: 74.71  Med: 106.82 Max: 116.18
Current: 74.71
74.71
116.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -10.40
CSII's 3-Year Average Share Buyback Ratio is ranked lower than
67% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. CSII: -10.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
CSII' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -242.8  Med: -47.9 Max: -10.4
Current: -10.4
-242.8
-10.4

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 29.57
CSII's Price-to-Net-Cash is ranked lower than
64% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. CSII: 29.57 )
Ranked among companies with meaningful Price-to-Net-Cash only.
CSII' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 0.54  Med: 11.98 Max: 231.2
Current: 29.57
0.54
231.2
Price-to-Net-Current-Asset-Value 12.93
CSII's Price-to-Net-Current-Asset-Value is ranked lower than
68% of the 206 Companies
in the Global Medical Devices industry.

( Industry Median: 6.88 vs. CSII: 12.93 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
CSII' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.53  Med: 6.88 Max: 27.54
Current: 12.93
0.53
27.54
Price-to-Tangible-Book 9.19
CSII's Price-to-Tangible-Book is ranked lower than
75% of the 263 Companies
in the Global Medical Devices industry.

( Industry Median: 4.11 vs. CSII: 9.19 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
CSII' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.52  Med: 6.15 Max: 12.81
Current: 9.19
0.52
12.81
Price-to-Median-PS-Value 2.14
CSII's Price-to-Median-PS-Value is ranked lower than
89% of the 242 Companies
in the Global Medical Devices industry.

( Industry Median: 1.03 vs. CSII: 2.14 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
CSII' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.29  Med: 1.05 Max: 2.93
Current: 2.14
0.29
2.93
Earnings Yield (Greenblatt) % -3.24
CSII's Earnings Yield (Greenblatt) % is ranked lower than
68% of the 432 Companies
in the Global Medical Devices industry.

( Industry Median: 2.17 vs. CSII: -3.24 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
CSII' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -3.35  Med: 32 Max: 5408.1
Current: -3.24
-3.35
5408.1

More Statistics

Revenue (TTM) (Mil) $192.8
EPS (TTM) $ -0.87
Beta2.32
Short Percentage of Float3.90%
52-Week Range $13.16 - 30.21
Shares Outstanding (Mil)32.60

Analyst Estimate

Jun17 Jun18
Revenue (Mil $)
EPS ($) -0.08 0.15
EPS without NRI ($) -0.08 0.15
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for CSII

Headlines

Articles On GuruFocus.com
Cardiovascular Systems, Inc. Secures $40 Million Line of Credit from Silicon Valley Bank Apr 04 2017 
Stocks Mario Gabelli Has Bought for 2 Quarters Jun 20 2016 
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Cardiovascular Syste Feb 16 2016 
Stocks Bill Frels Keeps On Buying Nov 17 2015 
Mairs & Power Small Cap Fund Comments on Cardiovascular Systems Oct 20 2014 
Mairs & Power Small Cap Fund Q3 2014 Commentary Oct 20 2014 
Weekly CEO Sells Highlight: Google Inc, Infromatica Corp, Deckers Outdoor Corp and Cardiovascular Sy Aug 14 2011 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 13,170 Shares Nov 19 2010 
CARDIOVASCULAR SYSTEMS, INC. (CSII) President and CEO David Martin sells 39,330 Shares Nov 17 2010 
CARDIOVASCULAR SYSTEMS, INC. Reports Operating Results (10-Q) Nov 12 2010 

More From Other Websites
Zacks.com featured highlights: Cabot Oil & Gas, Cardiovascular Systems, Fortress Transportation and... Apr 26 2017
Thousands in Phoenix May Be Affected by Peripheral Artery Disease (PAD) Apr 18 2017
Thousands in Dallas May Be Affected by Peripheral Artery Disease (PAD) Apr 18 2017
Thousands in Philadelphia May Be Affected by Peripheral Artery Disease (PAD) Apr 18 2017
Thousands in Nashville May Be Affected by Peripheral Artery Disease (PAD) Apr 18 2017
Cardiovascular Systems Voluntarily Recalls 900 Pumps Apr 18 2017
Cardiovascular Systems Initiates Voluntary Recall of Saline Infusion Pump Apr 17 2017
Cardiovascular Systems to Webcast Fiscal 2017 Third-Quarter Earnings Conference Call Wednesday, May... Apr 05 2017
Cardiovascular Systems, Inc. Secures $40 Million Line of Credit from Silicon Valley Bank Apr 04 2017
Cardiovascular Systems, Inc. Receives Approval for the Diamondback 360® Coronary Orbital... Mar 30 2017
Cardiovascular Systems, Inc. Receives Approval for the Diamondback 360® Coronary Orbital... Mar 30 2017
Cardiovascular Systems Enrolls First Subject in ECLIPSE Coronary Clinical Trial Mar 28 2017
Cardiovascular Systems, Inc. breached its 50 day moving average in a Bullish Manner : CSII-US :... Mar 23 2017
STERIS Continues to Trade Below Industry on Dull Outlook Mar 16 2017
Integra (IART) Titan Reverse Launch Expands Extremity Line Mar 16 2017
IDEXX (IDXX) Poised on Strong Fundamentals, Innovations Mar 15 2017
Medtronic's Pacemaker Business Wins CMS Coverage Approval Mar 14 2017
The Zacks Analyst Blog Highlights: Inogen, OraSure Technologies, Lannett and Cardiovascular Systems Mar 10 2017
Amedisys Stock Up on Solid Earnings, Reimbursement Woes Stay Mar 03 2017
VWR Corp Poised on Strong Earnings Amid Currency Headwinds Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)